Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Ingimarsson, OddurMacCabe, James H
Haraldsson, Magnús
Jónsdóttir, Halldóra
Sigurdsson, Engilbert
Issue Date
2017-10
Metadata
Show full item recordCitation
Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. 2017, 71 (7):496-502 Nord J PsychiatryAbstract
Type 2 diabetes (T2D) and raised blood lipids are associated with the use of antipsychotics, not least clozapine.To describe the prevalence of high blood glucose levels, T2D, and dyslipidemia, in association with the use of clozapine or other antipsychotics in patients with schizophrenia in Iceland.
This study identified 188 patients treated with clozapine and 395 patients never treated with clozapine by searching the electronic health records of Landspitali, the National University Hospital. The comparison group consisted of Icelandic population controls. Data were obtained on blood glucose, HbA1c, and blood lipid levels from these health records.
The prevalence of T2D was 14.3% in the clozapine group, where the mean age was 51.2 years, and 13.7% in the never-on-clozapine group, where the mean age was 58.6 years. Males on clozapine were 2.3-times more likely and females 4.4-times more likely to have developed T2D than controls from an age-adjusted Icelandic cohort, while males on other antipsychotics were 1.5-times more likely and females 2.3-times as likely to have T2D than controls. Only one case of ketoacidosis was identified. Triglyceride levels were significantly higher in both treatment groups compared to controls in the age-adjusted Icelandic cohort.
Clinicians must take active steps to reduce the risk of T2D and raised triglycerides in patients with schizophrenia. Antipsychotics were associated with a greater risk of T2D developing in females compared to males.
Description
To access publisher's full text version of this article click on the hyperlink belowRights
Archived with thanks to Nordic journal of psychiatryae974a485f413a2113503eed53cd6c53
10.1080/08039488.2017.1334821
Scopus Count
Collections
Related articles
- Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.
- Authors: Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E
- Issue date: 2016 Dec 12
- Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records.
- Authors: Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E
- Issue date: 2016 Aug
- Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland.
- Authors: Ingimarsson O, MacCabe JH, Sigurdsson E
- Issue date: 2018 Oct
- Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
- Authors: Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W
- Issue date: 2005 Jun
- Hyperglycemia and antipsychotic medications.
- Authors: Haupt DW, Newcomer JW
- Issue date: 2001